. Par, AOD) ne sont pas, pour l'instant, des traitements de première intention dans la prévention du risque thromboembolique en cas de FA. Ils restent une alternative aux AVK, surtout chez les patients pour lesquels il est difficile d'équilibrer l'INR. Les AVK resteront utiles encore longtemps, et notamment chez les personnes âgées

A. Les, les anticoagulants de référence en cas de FA, notamment chez les sujets âgés à haut risque d'insuffisance rénale et donc de surdosage. L'amélioration de l'équilibre des AVK reste donc plus que jamais nécessaire

P. Pouyanne, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres, BMJ, issue.7241, pp.320-1036, 2000.

A. European-heart-rhythm, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Europace, issue.10, pp.12-1360, 2010.

I. M. Ogilvie, Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review, The American Journal of Medicine, vol.123, issue.7, pp.638-645, 2010.
DOI : 10.1016/j.amjmed.2009.11.025

E. M. Hylek, Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation, Stroke, vol.37, issue.4, pp.1075-80, 2006.
DOI : 10.1161/01.STR.0000209239.71702.ce

A. S. Go, Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.285-2370, 2001.
DOI : 10.1001/jama.285.18.2370

J. Heeringa, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, European Heart Journal, vol.27, issue.8, pp.27-949, 2006.
DOI : 10.1093/eurheartj/ehi825

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.22-983, 1991.
DOI : 10.1161/01.STR.22.8.983

W. M. Feinberg, Analysis and implications Epidemiology and natural history of atrial fibrillation: clinical implications Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project) Stroke, Prevalence Arch Intern Med J Am Coll Cardiol Circulation, vol.155, issue.11422, pp.469-73, 1995.

C. Marini, Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study, Stroke, vol.36, issue.6, pp.36-1115, 2005.
DOI : 10.1161/01.STR.0000166053.83476.4a

A. K. Kakkar, International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD), American Heart Journal, vol.163, issue.1, pp.13-19, 2012.
DOI : 10.1016/j.ahj.2011.09.011

G. Thrall, Quality of Life in Patients with Atrial Fibrillation: A Systematic Review, The American Journal of Medicine, vol.119, issue.5, pp.448-449, 2006.
DOI : 10.1016/j.amjmed.2005.10.057

P. Dorian, The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy, Journal of the American College of Cardiology, vol.36, issue.4, pp.1303-1312, 2000.
DOI : 10.1016/S0735-1097(00)00886-X

A. K. Das, The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation, Age and Ageing, vol.36, issue.1, pp.95-102, 2007.
DOI : 10.1093/ageing/afl062

M. Debray, Anticoagulation orale en pratique g??riatrique, La Revue de M??decine Interne, vol.24, issue.2, pp.107-124, 2003.
DOI : 10.1016/S0248-8663(02)00020-6

V. Siguret, Vitamin K: metabolism, physiopathology, implication in the inter-and intra-individual variability in the response to the vitamin K antagonists. hématologie Les médicaments antivitamine K (AVK) : conseils pratiques pour le personnel soignant. Afssaps Anticoagulation therapy in the elderly: specials considerations. Rev Hematologie, pp.389-99, 2006.

B. Furie and M. Pirmohamed, A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med N Engl J Med A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. N Engl J Med, vol.25, issue.2612, pp.146-857, 2007.

E. M. Hylek, An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation, New England Journal of Medicine, vol.335, issue.8, pp.540-546, 1996.
DOI : 10.1056/NEJM199608223350802

S. J. Connolly, Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range, Circulation, vol.118, issue.20, pp.118-2029, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.750000

A. M. Gallagher, Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients, Thrombosis and Haemostasis, vol.106, issue.5, pp.968-77, 2011.
DOI : 10.1160/TH11-05-0353

F. R. Rosendaal, A method to determine the optimal intensity of oral anticoagulant therapy Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review, Thromb Haemost Circ Cardiovasc Qual Outcomes, vol.69, issue.12, pp.236-245, 1993.

C. L. Morgan, Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control, Thrombosis Research, vol.124, issue.1, pp.37-41, 2009.
DOI : 10.1016/j.thromres.2008.09.016

L. A. , P. T. Choi, J. D. Douketis, and E. , Décembre 2007. 38 ENEIS: Etude nationale sur les évènements graves liés aux soins Hémorragies du système nerveux central associées à un traitement AVK : facteurs de risqueEnquête menée avec les Services de Neurochirurgie français par l'Association des Centres Régionaux de Pharmacovigilance. Afssaps Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. ann intern med Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis, EMIR : Effets indésirables des Médicaments : Incidence et Risque, sur les hospitalisations liées à un effet indésirable médicamenteux. Coordination CRPV de Bordeaux DREES. Etudes et Résultats n°398, mai 2005 et Série Etudes et Recherches n°110, pp.13-25, 2000.

G. Palareti, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy, Lancet, issue.9025, pp.348-423, 1996.

E. M. Hylek, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, pp.115-2689, 2007.

N. Kagansky, Safety of Anticoagulation Therapy in Well-informed Older Patients, Archives of Internal Medicine, vol.164, issue.18, pp.2044-50, 2004.
DOI : 10.1001/archinte.164.18.2044

B. F. Gage, Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.285-263, 2001.
DOI : 10.1001/jama.285.22.2864

D. Poli, Stroke Risk Stratification in a ???Real-World??? Elderly Anticoagulated Atrial Fibrillation Population, Journal of Cardiovascular Electrophysiology, vol.101, issue.1, pp.25-30, 2011.
DOI : 10.1111/j.1540-8167.2010.01858.x

B. F. Gage, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Am Heart J J Am Coll Cardiol Chest, vol.151, issue.515, pp.713-722, 2006.

V. Roldan, Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a ???Real-World??? Population With Atrial Fibrillation Receiving Anticoagulant Therapy, Chest, vol.143, issue.1, pp.179-84, 2013.
DOI : 10.1378/chest.12-0608

A. J. Camm, 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.2719-2766, 2008.
DOI : 10.1016/j.rec.2012.11.003

C. Manotti, Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment), Haematologica, issue.10, pp.86-1060, 2001.

C. Héritier, A. N. Guyen, and J. P. Cambus, Comment réduire les risques des AVK? Utilisation d'un logiciel d'aide à la prescription, Rev Prat, vol.21, pp.754-755, 2007.

P. Imbert, Evaluation of a mobile electronic assistant to aid in fluindione prescription: The INRPlus cluster randomized trial, Thrombosis Research, vol.133, issue.5, pp.756-61, 2014.
DOI : 10.1016/j.thromres.2014.02.003

C. Heneghan, Self-monitoring of oral anticoagulation: a systematic review and meta-analysis Evaluation de l'autosurveillance de l'INR chez les patients adultes traités par antivitamines K en vue de la prise encharge par l'assurance maladie des dispositifs d'automesure de l'INR. HAS, Lancet, vol.65, issue.9508, pp.367-404, 2006.

P. Leger, C. J. Boneu, B. Boccalon, H. Cambus, J. P. Magnin et al., Les cliniques d'anticoagulants. Sang Thrombose Vaisseaux Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists, Prise en charge des surdosages, des accidents et du risque hémorragique liés à l'utilisation des antivitamines K. HAS, pp.288-90, 2003.

I. Mahé, B. D. Duru, G. Lamarque, H. Bergmann, J. Drouet et al., Use and monitoring of vitamin K antagonists in everyday medical practice. French results of the international ISAM study of patients with nonvalvular atrial fibrillation, Presse Med, pp.1797-803, 1935.

J. Ansell, Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic nonvalvular atrial fibrillation: the international study of anticoagulation management (ISAM) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, J Thromb Thrombolysis Lancet, vol.23, issue.29921, pp.383-955, 2007.

L. Wallentin, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial(9745): p. 975-83. 73. Lecroart, I., Traitement anti-coagulant au long cours par anti-vitamines K: qualité de la prise en charge et suivi biologique en Aquitaine Rev Prat Med Gen, Lancet, vol.19, pp.376-235, 2005.

K. E. Suivi-biologique-du-traitement-par-antivitamine and V. , Etude menée auprès des laboratoires d'analyses médicales. Afssaps http://ansm.sante.fr/var/ansm_site/storage/original/application Anticoagulants chez le sujet âgé, Rev Prat Med Gen, vol.777, issue.776, p.21, 2003.

K. En-Île-de-france and D. A. , Union Régionale des caisses d'assurance maladie d'Île-de-France Does the Birmingham model of oral anticoagulation management in primary care work outside trial conditions?, Br J Gen Pract, vol.308961, issue.471, pp.51-828, 2001.

M. R. Patel, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-92, 2011.
DOI : 10.1056/NEJMoa1107039

R. P. Giulgliano, C. T. Ruff, and E. Braunwald, Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013.
DOI : 10.1056/NEJMoa1310907

W. Ageno, Oral Anticoagulant Therapy, Chest, vol.141, issue.2, pp.44-88, 2012.
DOI : 10.1378/chest.11-2292

. Dabigatran, Fibrillation auriculaire non valvulaire Quelle place pour les anticoagulants oraux non antivitamine K : apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®). HAS 2013, pp.32-835, 2012.